REUMATOLOGISK SPECIALLÆGEKLINIK ApS LONE SVENDSEN

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.3% 1.5% 1.8% 7.6% 9.5%  
Credit score (0-100)  80 76 69 31 25  
Credit rating  BBB BBB BBB B B  
Credit limit (kDKK)  28.9 10.0 2.1 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Net sales  0 0 0 0 0  
Gross profit  2,125 2,158 2,500 3,789 -74.6  
EBITDA  785 1,082 1,216 2,670 -74.6  
EBIT  620 976 1,176 2,653 -74.6  
Pre-tax profit (PTP)  619.8 975.1 1,170.4 2,469.3 -16.7  
Net earnings  483.4 760.4 945.8 1,882.6 -16.7  
Pre-tax profit without non-rec. items  620 975 1,170 2,469 -16.7  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Tangible assets total  203 155 117 0.0 0.0  
Shareholders equity total  1,282 934 1,880 3,650 3,519  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,639 1,494 2,364 4,201 3,551  

Net Debt  -1,072 -926 -1,836 -3,917 -3,529  
 
See the entire balance sheet

Volume 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,125 2,158 2,500 3,789 -74.6  
Gross profit growth  5.4% 1.6% 15.8% 51.5% 0.0%  
Employees  2 2 2 1 0  
Employee growth %  0.0% 0.0% 0.0% -50.0% -100.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,639 1,494 2,364 4,201 3,551  
Balance sheet change%  31.4% -8.8% 58.2% 77.7% -15.5%  
Added value  620.1 976.3 1,175.9 2,652.6 -74.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -310 -154 -79 -134 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 -1.0  

Profitability 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  29.2% 45.2% 47.0% 70.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  43.0% 62.3% 61.0% 83.0% -0.4%  
ROI %  58.6% 87.6% 83.6% 98.5% -0.4%  
ROE %  46.5% 68.6% 67.2% 68.1% -0.5%  

Solidity 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Equity ratio %  78.2% 62.5% 79.5% 86.9% 99.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -136.6% -85.6% -151.0% -146.7% 4,727.6%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Quick Ratio  3.8 2.2 4.4 7.6 111.3  
Current Ratio  3.8 2.2 4.4 7.6 111.3  
Cash and cash equivalent  1,072.2 926.3 1,836.2 3,916.7 3,528.8  

Capital use efficiency 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  983.9 671.6 1,655.9 2,838.8 2,657.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/9
2020
2020/9
2021
2021/9
2022
2022/9
2023
2023/9
Net sales / employee  0 0 0 0 0  
Added value / employee  310 488 588 2,653 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  392 541 608 2,670 0  
EBIT / employee  310 488 588 2,653 0  
Net earnings / employee  242 380 473 1,883 0